Every 8-K that Y-mAbs Therapeutics, Inc. (YMAB) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow YMAB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full YMAB filings page.
Y-mAbs Therapeutics announced a merger agreement that converts outstanding equity awards into cash at the Effective Time. The Agreement and Plan of Merger dated August 4, 2025 is referenced and exhibits including the amended certificate and bylaws are filed. All stock options outstanding immediately before the Effective Time are cancelled and converted into a cash payment equal to the number of shares covered multiplied by the excess of the Merger Consideration over the option exercise price; options with an exercise price at or above the Merger Consideration are cancelled for no consideration. Restricted stock units (RSU Awards) convert into cash equal to the shares issuable multiplied by the Merger Consideration, while performance-based RSUs (PSU Awards) convert into cash based on the maximum number of shares issuable multiplied by the Merger Consideration. The filing references the merger agreement and supporting exhibits but does not disclose the numeric Merger Consideration within the provided text.
Y-mAbs Therapeutics reported that it has announced its financial results for the quarter ended June 30, 2025 and furnished a related press release as Exhibit 99.1 to this Form 8-K. The filing states that the material furnished, including Exhibit 99.1, is not to be deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings except by specific reference.
The text of this 8-K does not include any financial metrics or operating results; an Interactive Data File (Inline XBRL) is included as Exhibit 104. Investors must review the attached press release for the actual financial details.